PHARMACY

Takeda to investigate interactions of anti-clotting drugs, PPIs in GERD

BY Alaric DeArment

DEERFIELD, Ill. A research and development arm of Japanese drug maker Takeda has started a clinical trial to investigate potential interactions between a popular cardiovascular drug and drugs used to treat gastroesophageal reflux disease.

Takeda Global Research & Development Center announced Tuesday that it was evaluating published data and communications from the Food and Drug Administration regarding potentially harmful drug interactions associated with use of the anticlotting drug Plavix (clopidogrel), made by Sanofi-Aventis and Bristol-Myers Squibb, and certain proton-pump inhibitors, particularly its drug Kapidex (dexlansoprazole).

The FDA recommended that patients using Plavix avoid taking certain PPIs, especially AstraZeneca’s Prilosec (omeprazole) and Nexium (esomaprazole), after studies showed that the drugs inhibited a certain liver enzyme that Plavix requires to function, thus reducing Plavix’s effectiveness. The effect of other PPIs, such as Kapidex, on the effectiveness of Plavix remains uncertain.

The trial is enrolling patients and is expected to be finished this year, Takeda said.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Pfizer teams up with Keas

BY Alaric DeArment

NEW YORK Drug maker Pfizer will work with health information service Keas to allow health-and-wellness experts to write, sell and distribute personalized online care plans directly to patients, the two companies announced Monday.

Keas is a company that provides care plans written by pharmacists, doctors and nutritionists. Companies that have published care plans on Keas have included CVS MinuteClinic, DiabetesMine, HealthWise and Dr. Greene Pediatrics. The Web site includes a personalized “dashboard” that allows users to keep track of their personal health goals and help them make healthcare decisions.

“Our partnership with Keas demonstrates Pfizer’s commitment to invest in innovative and game-changing solutions that empower patients and physicians to further engage in the patient’s health,” Pfizer SVP worldwide strategy and innovation Kristin Peck said. “This is a further testimony of Pfizer’s commitment to remain the partner of choice for entrepreneurs and innovators.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Cornerstone moves drug testing site for investigational cancer treatment

BY Alaric DeArment

CRANBURY, N.J. Early- and mid-stage clinical trials of an investigational drug for treating cancer have a new testing site, the drug’s developer said Monday.

Privately owned drug maker Cornerstone Pharmaceuticals announced that the phase 1 and phase 2 trials of the drug CPI-613 would include a site owned by Pivotal Research Centers in Peoria, Ariz. CPI-613 is part of a new drug class developed using Cornerstone’s Altered Energy Metabolism Directed technology platform designed to target metabolic changes that may be common to many cancer types. The Food and Drug Administration has given the drug orphan drug status for pancreatic cancer.

“This is a very significant development for our company as we expand the clinical trials of CPI-613 and continue to partner with institutions that share our vision of helping people to better manage their affliction,” Cornerstone CEO Robert Shorr said.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES